Adaptimmune Therapeutics (ADAP) Downgraded by ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a buy rating to a hold rating in a research note issued to investors on Sunday.

Several other equities research analysts also recently commented on ADAP. BidaskClub downgraded shares of Adaptimmune Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 4th. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a hold rating to a sell rating in a research report on Tuesday, July 10th. TheStreet downgraded shares of Adaptimmune Therapeutics from a c- rating to a d+ rating in a research report on Monday, July 16th. Cowen reiterated a buy rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, July 18th. Finally, Guggenheim initiated coverage on shares of Adaptimmune Therapeutics in a research report on Monday, September 17th. They set a buy rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $15.44.

NASDAQ:ADAP opened at $6.00 on Friday. Adaptimmune Therapeutics has a one year low of $5.73 and a one year high of $14.63. The company has a market cap of $588.21 million, a P/E ratio of -7.50 and a beta of 1.06.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. The business had revenue of $9.04 million for the quarter, compared to analyst estimates of $7.76 million. Analysts predict that Adaptimmune Therapeutics will post -1.01 earnings per share for the current year.

In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total value of $256,250.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of the company’s stock in a transaction dated Friday, September 7th. The stock was purchased at an average price of $1.67 per share, for a total transaction of $5,010,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ADAP. BNP Paribas Arbitrage SA acquired a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth approximately $122,000. BB&T Securities LLC acquired a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth approximately $128,000. Jane Street Group LLC acquired a new position in shares of Adaptimmune Therapeutics during the 1st quarter valued at $168,000. Trexquant Investment LP acquired a new position in shares of Adaptimmune Therapeutics during the 2nd quarter valued at $178,000. Finally, Trellus Management Company LLC acquired a new position in shares of Adaptimmune Therapeutics during the 2nd quarter valued at $195,000. Hedge funds and other institutional investors own 59.09% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Further Reading: What are CEFs?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply